Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

GlobeNewswire June 14, 2022

Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

GlobeNewswire May 10, 2022

Bioasis Enters Into Research Collaboration With Janssen

GlobeNewswire April 11, 2022

Bioasis to Attend and Present at Upcoming Industry Conference

GlobeNewswire March 9, 2022

Bioasis Announces $200,000 Non-Brokered Private Placement

GlobeNewswire February 17, 2022

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021

GlobeNewswire January 20, 2022

Bioasis Announces Annual General Meeting Results

GlobeNewswire December 16, 2021

Bioasis to Attend and Present at Upcoming Industry Conferences

GlobeNewswire December 9, 2021

Bioasis Announces Annual General Meeting Details

GlobeNewswire November 29, 2021

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021

GlobeNewswire October 28, 2021

Bioasis to Attend Upcoming Industry Conferences

GlobeNewswire September 30, 2021

Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor

GlobeNewswire August 18, 2021

Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³(TM) Fusion Protein Comprising Iduronate-2-sulfatase

GlobeNewswire August 9, 2021

Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

GlobeNewswire July 29, 2021

Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager

GlobeNewswire July 20, 2021

Goodfood Market Corp. (FOOD) has announced record financial results for the third quarter of 2021. Revenues increased by $21.2 million year-over-year, while gross margin improved by 35 per cent compared to Q3 2020. Net loss also increased to $2 million, an increase of $4.7 million compared the same period last year. Amidst the record financial results, Goodfood also reported significant progress in its grocery strategy, with the lease of its first automated fulfilment centre in Ottawa and the

Jocelyn Aspa July 7, 2021

Bioasis Announces Positive Results From an Efficacy Study of xB3(TM)-IL-1RA in a Model of Multiple Sclerosis

GlobeNewswire July 7, 2021

Bioasis (TSXV:BTI) appoints Dave Jenkins as Chief Financial Officer

John Ballem  July 2, 2021

Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer

GlobeNewswire July 1, 2021

Bioasis Technologies (TSXV:BTI) announces research collaboration with Oxyrane UK

Jocelyn Aspa June 30, 2021